Código QR (código de barras bidimensional)

Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer

Background and purpose: Neoadjuvant therapy (NAT) has become standard therapy for early triple-negative breast cancer (TNBC). The aim of this study was to report real-world outcome of TNBC treated with NAT with or without pembrolizumab and to identify predictive factors for achieving pathologic comp...

תיאור מלא

שמור ב:
Principais autores: Johanna Mattson, Meeri Maunu, Juho Lähteenmaa, Peeter Karihtala, Suvi Tuohinen, Joonas Laaksolilja, Anders Ståhls, Tuomo Meretoja
פורמט: Artigo
שפה:Inglês
יצא לאור: Medical Journals Sweden 2026-02-01
סדרה:Acta Oncologica
נושאים:
Triple-negative breast cancer
neoadjuvant therapy
pembrolizumab
Neoadjuvant chemotherapy
real-word evidence
efficacy
גישה מקוונת:https://actaoncologica.se/actaoncologica/article/view/44896
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים